NYSE:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis → Trump’s arrest is phase one (From Porter & Company) (Ad) Free NBY Stock Alerts $3.44 -0.21 (-5.75%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$3.08▼$3.5550-Day Range$2.57▼$5.9552-Week Range$2.28▼$44.80Volume311,805 shsAverage Volume24.78 million shsMarket Capitalization$3.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get NovaBay Pharmaceuticals alerts: Email Address Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About NovaBay Pharmaceuticals Stock (NYSE:NBY)NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesMay 30 at 8:41 AM | investorplace.comWhy Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?May 29 at 5:22 PM | businesswire.comNovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate UpdatesMay 25, 2024 | americanbankingnews.comNovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.comMay 13, 2024 | seekingalpha.comNovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call TranscriptMay 13, 2024 | businesswire.comNovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye SymptomsMay 9, 2024 | businesswire.comNovaBay Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | businesswire.comNovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through AmazonMay 3, 2024 | businesswire.comNovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024April 22, 2024 | businesswire.comNovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesApril 19, 2024 | businesswire.comNovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder EquityMarch 28, 2024 | seekingalpha.comNovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | benzinga.comNovaBay Pharmaceuticals: Q4 Earnings InsightsMarch 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsMarch 25, 2024 | businesswire.comNovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024March 14, 2024 | businesswire.comNovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023February 21, 2024 | markets.businessinsider.comNioBay Metals closes option agreement to acquire Foothills propertySee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone510-899-8800Fax510-474-1577Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,640,000.00 Net Margins-80.76% Pretax Margin-79.99% Return on Equity-304.39% Return on Assets-81.20% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.75 Sales & Book Value Annual Sales$15.02 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-86.00Miscellaneous Outstanding Shares1,082,000Free Float37,793,000Market Cap$3.72 million OptionableNot Optionable Beta2.03 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $155.48kKey CompetitorsLumos PharmaNASDAQ:LUMOSensei BiotherapeuticsNASDAQ:SNSEiBioNYSE:IBIOPurple BiotechNASDAQ:PPBTSynlogicNASDAQ:SYBXView All Competitors NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed in 2024? NovaBay Pharmaceuticals' stock was trading at $7.14 at the beginning of the year. Since then, NBY shares have decreased by 51.8% and is now trading at $3.44. View the best growth stocks for 2024 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSE:NBY) issued its earnings results on Thursday, May, 9th. The company reported ($4.90) earnings per share (EPS) for the quarter. The company had revenue of $2.63 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 80.76% and a negative trailing twelve-month return on equity of 304.39%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split on Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include OpGen (OPGN) and Abbott Laboratories (ABT). How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NBY) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
